Legend Biotech (NASDAQ: LEGN)
Legend Biotech Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Legend Biotech Company Info
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
News & Analysis
After Jumping 48% in 1 Month, Is It Too Late to Buy Legend Biotech?
Legend's cell therapy seems like it's a winner, but it might be priced in already.
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.
Why Legend Biotech's Shares Jumped 11.8% on Wednesday
Investors, on second glance, might think the company's stock offering is a good idea.
2 Biotechs With Recent FDA Approvals to Hold for the Next Decade
With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.
A 10-Bagger in 5 Years? These Healthcare Stocks Could Pull It Off.
Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.
Why Legend Biotech Shares Plummeted 17.6% Wednesday
The clinical-stage biotech company's stock dropped more than $4 a share from its Tuesday close.
2 Upcoming FDA Approval Decisions That Investors Should Really Watch
The FDA is scheduled to announce these two key approval decisions in late November.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.